Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.


Options:
A: Arm Label: NVA237 + indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 50 µg and indacaterol 150 µg | Arm Label: Placebo to NVA237 + indacaterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to NVA237 and indacaterol 150 µg | Intervention Type: DRUG; Name: NVA237 50 µg and indacaterol 150 µg; Assigned to Arm(s): NVA237 + indacaterol | Intervention Type: DRUG; Name: Placebo to NVA237 and indacaterol 150 µg; Assigned to Arm(s): Placebo to NVA237 + indacaterol
B: Arm Label: Aclidinium/Formoterol 400/6 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium/Formoterol 400/12 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate | Arm Label: Aclidinium monotherapy 400 μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Formoterol monotherapy 12 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/6 μg | Intervention Type: DRUG; Name: Aclidinium Bromide/Formoterol Fumarate; Assigned to Arm(s): Aclidinium/Formoterol 400/12 μg | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium monotherapy 400 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): Formoterol monotherapy 12 μg
C: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: NVA237; Type: EXPERIMENTAL; Interventions: Drug: NVA237, Drug: Placebo to tiotropium, Drug: salbutamol/albuterol | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to NVA237 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo to NVA237; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: salbutamol/albuterol; Assigned to Arm(s): NVA237

Answer: C